ReviewJournal of tissue engineering
Mechanism-guided biomaterial strategies for intervertebral disc degeneration: Pathological heterogeneity, functional classification, and translational perspectives.
Review in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is a multifactorial and clinically heterogeneous condition involving disturbances in oxidative balance, mitochondrial homeostasis, inflammatory signaling, susceptibility to regulated cell death, extracellular matrix integrity, and biomechanical function. Although biomaterial-based strategies have shown significant promise in preclinical studies, their clinical translation remains hindered by pathological heterogeneity, insufficient mechanistic validation, and frequent reliance on simplified experimental models. These models often fail to fully replicate the chronic, mechanically complex, and clinically diverse nature of human disc degeneration. In addition, current biomaterial strategies are commonly classified according to material composition or isolated molecular targets, potentially obscuring their functional objectives and limiting mechanistic comparisons across therapeutic platforms. This review presents a mechanism-guided framework for interpreting biomaterial interventions in IVDD. Biomaterial strategies are discussed based on their primary pathological targets and therapeutic intentions, including inflammatory regulation, restoration of redox homeostasis, mitochondrial protection, ferroptosis modulation, extracellular matrix preservation, and multifunctional microenvironment-responsive interventions. This framework acknowledges that these pathological processes are interconnected and vary in their relative dominance across clinical and pathological contexts and patient populations. We further analyze current biomaterial strategies according to mechanistic intervention layers, including upstream sensing and initiation-level control, restraint of intracellular amplification, organelle stabilization, regulation of execution checkpoints, and integration with higher-order structural organization. This layered perspective emphasizes that the efficacy of biomaterials depends not only on their composition but also on the pathological context, depth of regulatory influence, mechanistic specificity, and compatibility across intervention layers. Collectively, this review provides an integrated, mechanism-oriented framework for biomaterial design, preclinical evaluation, and translational development in IVDD therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.